Technical Analysis for CYDY - Cytodyn Inc

Grade Last Price % Change Price Change
grade A 1.2 4.80% 0.0550
CYDY closed up 4.8 percent on Tuesday, January 28, 2020, on 1.83 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical CYDY trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
New 52 Week High Strength 0.00%
Parabolic Rise Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Older signals for CYDY ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.
Biotechnology Medical Specialties Antibodies Hiv Hiv/Aids Viruses Antiviral Drug Lentiviruses Animal Virology

Is CYDY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.25
52 Week Low 0.0552
Average Volume 2,440,833
200-Day Moving Average 0.4634
50-Day Moving Average 0.6403
20-Day Moving Average 1.0227
10-Day Moving Average 1.0860
Average True Range 0.1023
ADX 44.11
+DI 34.3763
-DI 10.7278
Chandelier Exit (Long, 3 ATRs ) 0.9431
Chandelier Exit (Short, 3 ATRs ) 0.9269
Upper Bollinger Band 1.1981
Lower Bollinger Band 0.8473
Percent B (%b) 1.01
BandWidth 34.3014
MACD Line 0.1404
MACD Signal Line 0.1459
MACD Histogram -0.0055
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.3350
Resistance 3 (R3) 1.3367 1.2933 1.3125
Resistance 2 (R2) 1.2933 1.2590 1.2925 1.3050
Resistance 1 (R1) 1.2467 1.2377 1.2700 1.2450 1.2975
Pivot Point 1.2033 1.2033 1.2150 1.2025 1.2033
Support 1 (S1) 1.1567 1.1690 1.1800 1.1550 1.1025
Support 2 (S2) 1.1133 1.1477 1.1125 1.0950
Support 3 (S3) 1.0667 1.1133 1.0875
Support 4 (S4) 1.0650